Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Neuzil KM"" wg kryterium: Autor


Tytuł:
Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season.
Autorzy:
Hartert TV
Neuzil KM
Shintani AK
Mitchel EF Jr.
Snowden MS
Wood LB
Dittus RS
Griffin MR
Hartert, Tina V
Neuzil, Kathleen M
Shintani, Ayumi K
Mitchel, Edward F Jr
Snowden, Mary S
Wood, Lesa B
Dittus, Robert S
Griffin, Marie R
Pokaż więcej
Źródło:
American Journal of Obstetrics & Gynecology; Dec2003, Vol. 189 Issue 6, p1705-1712, 8p
Czasopismo naukowe
Tytuł:
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.
Autorzy:
Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.
Blette B; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Montefiori DC; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Deng W; Moderna, Inc., Cambridge, MA 02139, USA.
Zhou H; Moderna, Inc., Cambridge, MA 02139, USA.
Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Martins K; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
McDanal C; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Eaton A; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Sarzotti-Kelsoe M; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kenny A; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
Carone M; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
Huynh C; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Miller J; Moderna, Inc., Cambridge, MA 02139, USA.
El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Baden LR; Brigham and Women's Hospital, Boston, MA 02115, USA.
Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA.
Campbell TB; Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Clark J; Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Pajon R; Moderna, Inc., Cambridge, MA 02139, USA.
Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
On Behalf Of The Immune Assays
Moderna Inc
Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove
United States Government Usg/CoVPN Biostatistics Teams
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Sep 29; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
2019-nCoV Vaccine mRNA-1273*
COVID-19*/prevention & control
Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G ; Vaccine Efficacy
Czasopismo naukowe
Tytuł:
Characterization of Typhoid Intestinal Perforation in Africa: Results From the Severe Typhoid Fever Surveillance in Africa Program.
Autorzy:
Birkhold M; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Datta S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Pak GD; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.
Im J; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.
Ogundoyin OO; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria.
Olulana DI; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria.
Lawal TA; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria.
Afuwape OO; Division of Gastrointestinal Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria.
Kehinde A; Department of Medical Microbiology and Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Phoba MF; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo.
Nkoji G; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo.
Aseffa A; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia.
Teferi M; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia.
Yeshitela B; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia.
Popoola O; Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Owusu M; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Nana LRW; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso.
Cakpo EG; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso.
Ouedraogo M; Laboratorie d'Analyses Medicales, Hopital Protestant Schiphra, Ouagadougou, Burkina Faso.
Ouangre E; Service de Chirurgie Viscérale, Hopital Yalgado, Ouagadougou, Burkina Faso.
Ouedraogo I; Pediatric Department, Hopital Charles de Gaulle, Ouagadougou, Burkina Faso.
Heroes AS; Department of Tropical Bacteriology, Institute of Tropical Medicine, Antwerp, Belgium.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Jacobs J; Department of Tropical Bacteriology, Institute of Tropical Medicine, Antwerp, Belgium.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Mogeni OD; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.
Haselbeck A; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.
Sukri L; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Metila OL; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo.; Service de Microbiologie, Cliniques Universitaires de Kinshasa, Kinshasa, Democratic Republic of Congo.
Owusu-Dabo E; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Adu-Sarkodie Y; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Bassiahi AS; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso.
Rakotozandrindrainy R; Department of Microbiology and Parasitology, University of Antananarivo, Antananarivo, Madagascar.
Okeke IN; Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
Zellweger RM; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.
Marks F; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 02; Vol. 10 (Suppl 1), pp. S67-S73. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever.
Autorzy:
Nampota-Nkomba N; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
Carey ME; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK.
Jamka LP; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Fecteau N; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 02; Vol. 10 (Suppl 1), pp. S6-S12. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.
Autorzy:
Phillips MT; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA.
Antillon M; Swiss Tropical and Public Health Institute, Basel, Switzerland.
Bilcke J; Center for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp, Belgium.
Bar-Zeev N; International Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.
Limani F; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi.
Debellut F; Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland.
Pecenka C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
Neuzil KM; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Gordon MA; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Thindwa D; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Paltiel AD; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA.
Yaesoubi R; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA.
Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Mar 08; Vol. 23 (1), pp. 143. Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Humans ; Adolescent ; Cost-Effectiveness Analysis ; Vaccines, Conjugate ; Cost-Benefit Analysis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies